Avastin is a drug approved to treat colon cancer. It works by choking off blood vessels to the tumor. It turns out, however, that a tiny dose of the same drug, when injected into the eye can also stop the uncontrolled growth of blood vessels behind the retina that produces a leading cause of blindness in the elderly, macular degeneration. The good news is a compounding pharmacy can take the large dose in the Avastin package and split it into sterile eyeball-appropriate doses. The cost is somewhere between $20 and $100. That's good news for consumers, anyway. It wasn't such good news for Genentech, the maker of Avastin. So they went about making a small modification of the drug, renamed it Lucentis, and got FDA approval for its use in macular degeneration -- at $2000 per monthly injection. Avastin is not approved for the same purpose because Genentech has not applied for approval. It's still legal to use it off label, however, and numerous ophthalmologists have been doing so to save their patients and the taxpayers' money.

Genentech was not amused. So they announced in October they would no longer sell Avastin to compounding pharmacists.

The authors conclude that despite a widespread belief among doctors and patients that a strong sense of emotional well-being can improve survival in people living with cancer, multiple studies including this one refute such claims. Wrote the authors, "The belief that emotional well-being affects survival, nonetheless, has been remarkably resilient in the face of contrary data."